baber/WOPTO huggingface dataset:
Patent NZ-231624-A (NZ)
Title: Ganglioside derivatives, medicaments
Inventor: DELLA VALLE FRANCESCO
IPC: C07H15/10
Filed: 1989-12-04
Abstract: Novel N-acyl-lysogangliosides obtained from gangliosides by deacyation of the ceramide group, wherein the acyl group is derived from an aliphatic acid having from 2 to 24 carbon atoms, substituted by one or more polar groups. The N-acyl-lysogangliosides of the invention exhibit an inhibiting action on protein-kinase C activation and, thus, can be utilized in therapies for various pathologies of the nervous system.
Patent NZ-236353-A (NZ)
Title: Aqueous paper coating composition comprising particulate inorganic pigment and both anionic and cationic polyelectrolyte dispersant
Inventor: HUSBAND JOHN CLAUDE
IPC: C09D7/45
Filed: 1990-12-05
Abstract: There is disclosed an aqueous paper coating composition which comprises at least 45 % by weight of a particulate pigment dispersed with a dispersing agent, and an adhesive; characterised in that said dispersing agent comprises an anionic polyelectrolyte and a cationic polyelectrolyte, the cationic polyelectrolyte being present in an amount sufficient to render the particles cationic, in that said adhesive is a cationic or non-ionic adhesive and in that said particulate pigment is one which is not capable of being dispersed in water at high solids, and following vigorous mixing, in the sole presence of said cationic polyelectrolyte. Also disclosed is a method for making the paper coating composition, a method for coating a paper with a paper coating composition and the resulting coated paper. The coated paper of the invention is particularly suited to recycling.
Patent NZ-237855-A (NZ)
Title: Quinolonyl- substituted lactams; homologues, medicaments, and use
Inventor: DEMUTH THOMAS PROSSER
IPC: C07D501/28
Filed: 1991-04-17
Abstract: Antimicrobial quinolonyl lactam compounds comprising a lactam-containing moiety linked to a quinolone moiety, of the formula:   <IMAGE>   wherein (1) A1, A2, A3, R1, and R4 generally form any of a variety of quinolone, naphthyridine or related cyclic moieties known in the art to have antimicrobial activity; and (2) R6 is part of a linking moiety, linking the quinolone moiety to a lactam-containing moiety having the formula:   <IMAGE>   wherein (3) R10, R11, R12, R13, and R14, together with bonds "a" and "b", form any of a variety of lactam-containing moieties known in the art to have antimicrobial activity; and (4) the linking moiety includes (for example) carbamate, dithiocarbamate, urea, thiourea, isouronium, isothiouronium, guanidine, carbonate, trithiocarbonate, reversed carbamate, xanthate, reversed isouronium, reversed dithiocarbamate, reversed isothiouronium, amine, imine, ammonium, heteroarylium, ether, thioether, ester, thioester, amide, and hydrazide groups.
Patent NZ-246308-A (NZ)
Title: Iontophoresis apparatus: measurement and display of transferred charge
Inventor: HAAK RONALD P
IPC: A61N1/32
Filed: 1992-12-11
Abstract: Apparatus (11) for delivery of a medicament, drug or other therapeutic agent transdermally to a body by iontophoresis is provided. The apparatus (11) provides a means (13) for measuring and displaying the cumulative amount of the medicament delivered to the body by monitoring the amount of a metal, initially present at the anode (45), that is transferred to the cathode (41) in a subsidiary electrolyte cell (47) through which the drive current for the apparatus (11) passes. Optionally, the apparatus also provides a plurality of light emitting devices (63-1) that display a measure of the cumulative amount of medicament delivered, by use of visually distinguishable light colors or by use of binary encoding in the light display.
Patent NZ-266622-A (NZ)
Title: Keratinocyte growth factor fragment (kgf) with at least a 2-fold increase in mitogenic activity compared to a full length kgf; dna molecules, expression vectors, host cells, and conjugates
Inventor: GOSPODAROWICZ DENIS J
IPC: A61K47/48
Filed: 1994-04-28
Abstract: The present invention provides an isolated polypeptide, wherein said polypeptide is (a) a fragment of mature, full-length, human keratinocyte growth-factor (KGF) as depicted in Figure 1 or (b) an analog of said fragment, wherein said polypeptide exhibits an increase in bioactivity relative to said mature, full-length, human KGF as determined by the Balb/MK bioactivity assay.
Patent NZ-270633-A (NZ)
Title: Stable, microemulsion, all purpose, liquid cleaning composition
Inventor: ADAMY STEVEN
IPC: C11D1/825
Filed: 1995-03-03
Abstract: An improvement is described in microemulsion compositions which is more environmentally friendly, especially effective in the removal of oily and greasy soil and has an evidenced grease release effect, contains an anionic detergent, an esterfied ethoxylated glycerol type compound, a hydrocarbon ingredient, and water which comprises the use of a water-insoluble odoriferous perfume as the essential hydrocarbon ingredient in a proportion sufficient to form either a dilute o/w microemulsion composition containing, by weight, 0.1% to 6% of an anionic detergent, 0 to 16% of a nonionic surfactant, 0.1 to 50% of a cosurfactant, 0.1% to 20% of the esterfied ethoxylated glycerol type compound, 0.4% to 10% of perfume or a hydrocarbon and the balance being water.
Patent NZ-283096-A (NZ)
Title: Telecommunications system includes digital communication network for connecting multiple programmable telecommunication switches to form a switching system
Inventor: MADONNA ROBERT P
IPC: H04L12/56
Filed: 1995-03-06
Abstract: An open, high speed, high bandwidth digital communication network for connecting multiple programmable telecommunications switches to form a large capacity, non-blocking switching system. Each network switching node includes circuitry for transmitting and receiving variable-length, packetized information over the network, thus enabling each node to receive information from or transmit information to all other nodes. The network may carry any type of information present in the system including voice, data, video, multimedia, control, configuration and maintenance, and the bandwidth of the network may be divided or shared across various information types. Devices such as voice processing resources may also interface with the network, thereby gaining direct access to all information passing through the network. Also provided are methods and packet structures for communicating information over the network. Multiple networks may be interconnected to provide even greater switching capacity or voice processing capacity.
Patent NZ-305920-A (NZ)
Title: Seat with inflatable compartments for lifting occupant
Inventor: JEANS EDWARD LEWIS
IPC: A61G5/14
Filed: 1996-04-25
Abstract: PCT No. PCT/GB96/01001 Sec. 371 Date Oct. 24, 1997 Sec. 102(e) Date Oct. 24, 1997 PCT Filed Apr. 25, 1996 PCT Pub. No. WO96/33685 PCT Pub. Date Oct. 31, 1996A seating device which comprises an inflatable seat (4) and an inflating means which provides for the controlled inflation and deflation of the seat. The seat (4) comprises a chamber defined by top, bottom and side walls (12, 13) which is connected to the inflation means. The inflation means comprises a motorised fan unit (20) and a control valve (6) connected by a supply pipe (10) to the seat (4). The device is inflatable from a deflated position on the base of a support surface such as a bath to an inflated position adjacent the rim of the bath such that a person sitting thereon can easily enter or exit the bath to bathe. The device is of particular use for handicapped or elderly persons and does not require mechanical actuation means and has sufficient inflatable characteristic to enable the seat to remain in a fixed position in relation to the bath.
Patent NZ-330767-A (NZ)
Title: DNA encoding PauA, a plasminogen activator protein derived from streptococcus uberis, and a vaccine for treating bovine mastitis
Inventor: ROSEY EVERETT LEE
IPC: C07K19/00
Filed: 1998-06-22
Abstract: An isolated polynucleotide molecule, comprising a nucleotide sequence encoding a PauA protein from Streptococcus uberis, wherein the PauA protein comprises the amino acid sequence from amino acid 26 to amino acid 286 of Seq ID NO 2 or Seq ID No 4, a recombinant expression vector comprising the polynucleotide molecule above, method for preparing the polypeptide, vaccine, and kit.
Patent NZ-332136-A (NZ)
Title: Phenylalkylcarboxylic acid derivatives useful for treating hyperglycemia
Inventor: YANAGISAWA HIROAKI
IPC: C07D213/36
Filed: 1997-04-01
Abstract: Phenylalkylcarboxylic acid derivatives of the general formula: <CHEM> wherein R<1> represents an alkyl group and the like, R<2> represents an alkylene group, R<3> represents a hydrogen atom and the like, X represents a substituted or unsubstituted aryl group and the like, Y represents an oxygen atom and the like, Z represents an alkylene group and the like, and W represents an alkyl group and the like), the pharmacologically acceptable salts thereof or the pharmacologically acceptable esters thereof are useful as therapeutic or preventive agents for hyperglycemia and the like.
Patent NZ-336625-A (NZ)
Title: Sulfamide-metalloprotease inhibitors and their use in treating rheumatoid arthritis and other related diseases
Inventor: BROKA CHRIS ALLEN
IPC: C07D295/26
Filed: 1998-01-14
Abstract: The specification relates to sulfamides of formula (I), where the sulfamides are inhibitors of metalloproteases. Pharmaceutical compositions containing sulfamides of formula (I), methods for their preparation and their use in treating rheumatoid arthritis, osteoarthritis, osteoporosis, periodontal disease, chronic pulmonary obstructive disease, aberrant angiogenesis, multiple sclerosis, restenosis, aneurysmal disease, tumor metastasis, or corneal ulceration. Preferred compounds of formula (I) are illustrated below: N-hydroxy-2-(R)-{[4-(4-chlorophenoxy)piperidine-1-sulfonyl]amino}-3-methylbutyramide. N-hydroxy-2-(R)-{[4-(5-chloropyridin-2-yloxy)piperidine-1-sulfonyl]amino}-3-methylbutyramide. N-hydroxy-2-(R)-{[4-(4-fluorophenoxy)piperidine-1-sulfonyl]amino}-3-methylbutyramide. N-hydroxy-2-(R)-{[4-(4-chlorophenyl)piperazine-1-sulfonyl]amino}-3-methylbutyramide. N-hydroxy-2-(R)-{[4-(4-benzyloxyphenyl)piperazine-1-sulfonyl]amino}-3-methylbutyramide. N-hydroxy-2-(R)-{[4-(5-chloropyridin-2-yl)piperazine-1-sulfonyl]amino}-3-methylbutyramide. N-hydroxy-2-(R)-{[4-(2-phenylbenzoxazol-5-yl)piperazine-1-sulfonyl]amino}-3 -methylbutyramide. N-hydroxy-1-[4-(phenoxy)piperidine-1-sulfonyl]piperidine-2-(RS)-carboxamide N-hydroxy-1-[4-(phenylthio)piperidine-1-sulfonyl]piperidine-2-(RS)-carboxamide.
Patent NZ-337699-A (NZ)
Title: Tree harvesting machine comprising means for controlling movement of the tree-supporting part of the machine
Inventor: KARE ERKKI
IPC: A01G23/083
Filed: 1999-01-18
Abstract: A tree harvesting machine comprises a tree-supporting part 1 with a feeding means 2 for feeding a tree R in its longitudinal direction and a cross-cutting saw 5 for cutting the tree at selected locations.  Part 1 is supported by a boom assembly 6 or the like.  At the moment of action of saw 5, control means of the machine, having effect on the movement of part 1, induce movement F in part 1 which at least compensates the force which is caused by the weight of the tree and which tends to cleave the tree at the cutting point.
Patent NZ-503019-A (NZ)
Title: Signal transmission antenna mast
Inventor: KAEGEBEIN DANIEL P
IPC: H01Q1/12
Filed: 1998-03-30
Abstract: A ridged coaxial transmission line assembly including a plurality of parallel transmission paths is fabricated from an extrusion incorporating a plurality of slotted, longitudinal bores (11) provided with centrally located conductors (13) held in position by insulating stand-offs (14) provides a structure performing the dual functions of electrically integral antenna mast and signal conductors for a linear array of antenna elements supported by the mast.
Patent NZ-504791-A (NZ)
Title: Procedure and system for the transmission of information and setting up of a telecommunication connection
Inventor: GROHN TUOMO
IPC: H04Q3/00
Filed: 1998-12-21
Abstract: Procedure and system for optimisation of the route of a telecommunication connection to be set up in a telecommunication system comprising a mobile switching centre (MSC), a service switching point (SSP), a service control point (SCP), a gateway (GW) and a subscriber register (HLR). In the procedure, the service switching point (SSP) is connected to the service control point (SCP) and the gateway (GW) is connected to the service control point (SCP) and to the subscriber register (HLR). The telecommunication connection to be set up is directed via the service switching point (SSP) to the service control point (SCP). A database query is sent from the service control point (SCP) via the gateway (GW) to the subscriber register (HLR). The subscriber register provides routing information, on the basis of which an optimal route to the mobile switching centre under which the B-subscriber is located is determined.
Patent NZ-516294-A (NZ)
Title: Surfactant emulsions and structured surfactant systems
Inventor: HAWKINS JOHN
IPC: C11D3/34
Filed: 2000-06-22
Abstract: A mixture of an ethoxylated non-ionic surfactant having an average of 20 to 100 ethylene-oxy groups per molecule with from 10 to 150 parts by weight of a water soluble thiocyanate stabilises non-ionic emulsions and in particular deflocculated non-ionic structured surfactant systems by raising the lamellar/L2 phase transition temperature.
Patent NZ-517500-A (NZ)
Title: Device, system and method for on-line explosive deslagging
Inventor: ZILKA FRANCIS
IPC: F28G7/00
Filed: 1999-09-13
Abstract: A device, system and method permitting on-line explosives-based cleaning and deslagging of a fuel burning facility 31 such as a boiler, furnace, incinerator, or scrubber. A coolant, such as ordinary water, is delivered to the explosives 101 to prevent them from detonating due to the heat of the on-line facility. Thus, controlled detonation can be initiated as desired, and boiler scale and slag is removed without the need to shut down or cool down the facility. Alternative preferred embodiments include, but are not limited to: (1) using a non-liquid coolant, such as compressed air or other non-flammable gas, in place of the aforementioned liquid coolant; (2) using one or more highly-heat-resistant insulating materials to insulate the explosive and detonator cap, in place of or in addition to the aforementioned liquid or gaseous coolants; and (3) preparing and using a highly-heat-resistant explosive device 101, in place of or in addition to the aforementioned liquid or gaseous coolants, and/or the aforementioned highly-heat-resistant insulating materials in any desired combination.
Patent NZ-517605-A (NZ)
Title: Levosimendan solutions at a pH less than 5 particularly for intravenous administration
Inventor: BACKSTROM REIJO
IPC: A61P9/04
Filed: 2000-09-08
Abstract: Disclosed are levosimendan solutions for pharmaceutical use, and particularly for intravenous administration.  The solutions have enhanced stability and they are particularly useful as infusion or injection solutions or infusion concentrates.  Levosimendan is useful in the treatment of congestive heart failure.
Patent NZ-521603-A (NZ)
Title: Use of triazole compounds having amide linkage as antifungal agents
Inventor: UCHIDA TAKUYA
IPC: C07D417/14
Filed: 2001-03-27
Abstract: Compounds of formula (I) and their use in treating fungal infections.
Patent NZ-524363-A (NZ)
Title: Processes for preparing cilostazol (6-[4-(1-cyclohexyl- 1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone)
Inventor: MENDELOVICHI MARIOARA
IPC: C07B61/00
Filed: 2001-08-14
Abstract: Processes for preparing 6-[4-(1-cyclohexyl-1H-tetrazol- 5-yl)butoxy]-3,4-dihydro-2(1H-quinolinone of formula (I) which is also known by the generic name cilostazol are disclosed, wherein a process for preparing cilostazol of formula (I) comprises: (a) dissolving 6-hydroxy-3,4-dihydroquinolinone and a water- soluble base in water to form an aqueous phase, (b) dissolving a 1-cyclohexyl-5-(4-halobutyl)-tetrazole in a water-immiscible solvent to form an organic phase, (c) forming a biphasic mixture by contacting the aqueous phase and the organic phase in the presence of a quaternary ammonium phase transfer catalyst, (d) and recovering cilostazol from the biphasic mixture. Cilostazol inhibits cell platelet aggregation and is used to treat patients with intermittent claudication.
Patent NZ-527591-A (NZ)
Title: Binding domain-immunoglobulin fusion proteins
Inventor: LEDBETTER JEFFREY A
IPC: C07K19/00
Filed: 2002-01-17
Abstract: A binding domain-immunoglobin fusion protein comprises: a) a binding domain polypeptide that is fused to an immunoglobulin hinge region polypeptide, wherein said hinge region polypeptide is selected from the group consisting of: i) a mutated hinge region polypeptide that contains no cysteine residues and that is derived from a wild-type immunoglobulin hinge region polypeptide having one or more cysteine residues and that is not derived from IgG1; (ii) a mutated hinge region polypeptide that contains one cysteine residue and that is derived from a wildtype immunoglobulin hinge region polypeptide having two or more cysteine residues; (iii) a wild-type human IgA hinge region polypeptide; (iv) a mutated human IgA hinge region polypeptide that contains no cysteine residues and that is derived from a wildtype human IgA region polypeptide; and (v) a mutated human IgA hinge region polypeptide that contains one cysteine residue and that is derived from a wild-type human IgA region polypeptide; (b) an immunoglobulin heavy chain CH2 constant region polypeptide that is fused to the hinge region polypeptide; and (c) an immunoglobulin heavy chain CH3 constant region polypeptide that is fused to the CH2 constant region polypeptide; wherein: the binding domain-immunoglobulin fusion protein is capable of at least one immunological activity selected from the group consisting of antibody dependent cell-mediated cytotoxicity and complement fixation, and the binding domain polypeptide is capable of specifically binding to an antigen. A pharmaceutical composition comprising the fusion protein is useful for the treating a malignant condition or B-cell disorder, such as B-cell lymphoma, rheumatoid arthritis, myasthenia gravis, GraveÆs disease, type I diabetes mellitus, multiple sclerosis and an autoimmune disease.
Patent NZ-528318-A (NZ)
Title: Agents that modulate the interaction between PD-1 and its ligands are useful in the downmodulation of the immune response
Inventor: CARRENO BEATRIZ M
IPC: C12N5/0783
Filed: 2002-04-02
Abstract: An in vitro method for downmodulating activation of an immune cell, comprising contacting an immune cell, at the time of contact with an antigen, with an agent that inhibits signalling via PD-1 to downmodulate activation of the immune cell.
Patent NZ-529586-A (NZ)
Title: Deuterated 3-piperidinopropiophenone and medicaments containing said compounds
Inventor: ALKEN RUDOLF-GISBERT
IPC: C07D295/10
Filed: 2002-04-29
Abstract: The invention discloses deuterated 3-piperidinopropiophenones as well as their physiologically tolerated salts. Furthermore, the invention concerns the use of deuterated 3-piperidinopropiophenones for the treatment of muscular illnesses as well as for the preparation of pharmaceutical drugs for the treatment of muscular illnesses. In addition, the invention discloses pharmaceutical formulations containing deuterated 3-piperidinopropiophenones as well as their physiologically tolerated salts for the treatment of muscular illnesses in addition to containing pharmaceutically tolerated adjuvants and/or additives.
Patent NZ-531031-A (NZ)
Title: Cable release anchor
Inventor: ALBERSON DEAN C
IPC: E01F9/018
Filed: 2002-07-19
Abstract: A cable release anchor having an improved breakaway post design with a cable release feature. The cable release anchor includes upper and lower anchor portions that are readily separable from one another during an impact. A bearing plate is retained within the end of each of the upper and lower anchor portions, and each bearing plate has a bearing surface that is oriented at an acute angle with the vertical when installed in the ground. Each of these bearing plates contains a U-shaped cutout. When the upper and lower anchor portions are joined, the cutouts form an opening through which an end of the tension cable is disposed. An impact to the upper anchor portion readily releases the upper post section from the lower post section and frees the cable. The cable release anchor provides positive anchorage to react to tensile loads on a rail member to redirect a vehicle impacting along the length of the terminal or guardrail.
Patent NZ-533659-A (NZ)
Title: Nano-composite alloy carbon steel comprising martensite - austenite grains
Inventor: KUSINSKI GRZEGORZ J
IPC: C22C38/00
Filed: 2002-12-12
Abstract: Carbon steels of high performance are disclosed that contain dislocated lath structures in which laths of martensite alternate with thin films of austenite, but in which each grain of the dislocated lath structure is limited to a single microstructure variant by orienting all austenite thin films in the same direction. This is achieved by careful control of the grain size to less than ten microns. Further improvement in the performance of the steel is achieved by processing the steel in such a way that the formation of bainite, pearlite, and interphase precipitation is avoided.
Patent NZ-535367-A (NZ)
Title: A method for selecting cell lines to be used for nuclear transfer in mammalian species
Inventor: MELICAN DAVID
IPC: A01K67/00
Filed: 2003-03-25
Abstract: Disclosed is a method for cloning a non-human mammal comprising: (i) selecting differentiated non-human mammalian cells to be used as a source of donor cells or donor nuclei according to their nuclear index and cleavage and/or fusion rates; (ii) obtaining at least one oocyte from a mammal of the same species as the source of donor cells or donor nuclei; (iii) enucleating said at least one oocyte; (iv) transferring a donor cell or donor cell nucleus into the enucleated oocyte to form a cell couplet; (v) simultaneously fusing and activating the cell couplet to form an embryo, wherein the cell couplet is activated after an initial electrical shock; (vi) culturing said embryo until greater than the 2-cell developmental stage; and (vii) transferring said embryo into a host mammal such that the embryo develops into a fetus.
Patent NZ-539015-A (NZ)
Title: 4-aminopiperidine derivatives, processes for their preparation and their use as medicaments
Inventor: LAMBERTY YVES
IPC: A61P25/24
Filed: 2003-09-30
Abstract: Disclosed are 4-aminopiperidine compounds of formula (I), wherein: R1, R2, R3, and R4 are independently H, F, Cl, methyl or trifluoromethyl, with the proviso that if R1, R2, and R4 are H, then R3 is not H or halogen. The compounds of formula (I) are used in the manufacture of medicaments for the treatment of neurological diseases. Also disclosed are the intermediate compounds of formula (II), wherein: R1, R2, R3, and R4 are independently H, F, Cl, methyl and trifluoromethyl, with the proviso that if R1, R2 and R4 are H, then R3 is not H or halogen, P is an amine protecting group.
Patent NZ-539716-A (NZ)
Title: Precision disc tiller and safety device therefor
Inventor: EVIN MICHEL
IPC: A01B21/08
Filed: 2003-10-13
Abstract: The invention concerns a precision disc tiller (1) comprising a frame (2) equipped with at least one gang of non-motorized rotary discs (3) mounted respectively independent and oscillating relative to the support frame (2) via a safety device (5). Said disc tiller is characterized in that each disc (3) is linked to the frame (2) by a coil spring (6) forming at least one and a half turns, one end (6A) of the spring (6) being linkable to the frame (2) while the other end (6B) of the spring (6) is linkable to the hub (8) of the disc (3), said spring (6) being oriented such that the turn(s) of said spring are tightened by winding when the pressure exerted on the disc (3) is higher than the predetermined pressure allowing the disc to be vertically cleared (3) by being lifted.